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Abstract- The reliable diagnostic identification of neuropsychiatric disorders such as schizophrenia, 
bipolar disease, and depression has been associated with some biological markers (genomics, 
proteomics, metabolomics) but to date, these markers do not have the sensitivity/specificity of a 
diagnostic test. Biomarker tests that are relevant to global chronic disease are now applicable to 
neuropsychiatric diseases to prevent autoimmune disease, endoplasmic reticulum stress associated 
mitophagy with relevance to neuron apoptosis. Metabolic abnormalities has been linked to 
neuropsychiatric disorder with the careful nutritional assessment of patients reported in many published 
studies. Early interventions with genomic medicine now assist in the prevention of autoimmune disease 
associated with global chronic disease and neuropsychiatric disorders.  
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endoplasmic reticulum stress; amyloid beta; genomic medicine;  sirtuin 1; global; chronic disease; 
neurodegeneration. 
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Early Diagnosis and Nutritional Treatment 
Stabilizes Neuropsychiatric Disorders
Ian James Martins
Abstract- The reliable diagnostic identification of 
neuropsychiatric disorders such as schizophrenia, bipolar 
disease, and depression has been associated with some
biological markers (genomics, proteomics, metabolomics) but 
to date, these markers do not have the sensitivity/specificity of 
a diagnostic test. Biomarker tests that are relevant to global 
chronic disease are now applicable to neuropsychiatric 
diseases to prevent autoimmune disease, endoplasmic 
reticulum stress associated mitophagy with relevance to 
neuron apoptosis. Metabolic abnormalities has been linked to 
neuropsychiatric disorder with the careful nutritional 
assessment of patients reported in many published studies. 
Early interventions with genomic medicine now assist in the 
prevention of autoimmune disease associated with global 
chronic disease and neuropsychiatric disorders. Functional 
foods that contain appropriate doses of activators will allow 
modulation of neuropsychiatric diseases at the nuclear 
receptor level with the maintenance of neuron endoplasmic 
reticulum stress and the prevention of mitophagy associated 
with accelerated neurodegeneration.
Keywords: neuropsychiatric; schizophrenia; depression; 
bipolar disease; diagnosis; mitophagy; endoplasmic 
reticulum stress; amyloid beta; genomic medicine;  
sirtuin 1; global; chronic disease; neurodegeneration.
Abbreviations: NAFLD, non alcoholic fatty liver disease, 
ER, endoplasmic reticulum, LPS, bacterial 
lipopolysaccharides, NO, nitric oxide, Sirt 1, Sirtuin 1.
I. Introduction
euroscience research has become crucial to 
understand the complexity of neuropsychiatry 
disorders and assist with the diagnosis and 
treatment of the various disorders [1]. Neuropsychiatric 
disorders such as schizophrenia, depression, bipolar 
disease, autism, attention deficit hyperactivity disorder 
and neurodegenerative diseases such as Parkinson’s 
disease, Huntington’s disease, and Alzheimer’s disease 
have increased in various communities. The global 
chronic disease epidemic has indicated that 
nonalcoholic fatty liver disease (NAFLD) and diabetes 
(Figure 1) will reach epidemic levels with 30% of          
the population affected with complications such           
as cardiovascular disease, kidney disease and 
neurodegenerative diseases [2,3]. Neuropsychiatric 
disorders may now be connected to the global chronic 
disease epidemic [2] with early diagnosis essential to 
prevent accelerated neurodegeneration and to improve 
medical therapy in neuropsychiatric patients [4-6].
Figure 1: Connections between global chronic disease 
and neuropsychiatric disorders indicate insulin 
resistance and immune reactions interfere with the 
diagnosis and treatment of neuropsychiatric 
disturbances such as schizophrenia, depression, bipolar 
disorder, autism, and neurodegenerative diseases.
Insulin resistance in NAFLD, obesity, and 
diabetes involve autoimmune alterations in various 
tissues such as the adipose tissue, heart, liver and 
kidney that may determine accelerated brain aging and 
lifespan with relevance to neuropsychiatric disorders 
(Figure 1) [7-13]. The role of nutrition, lifestyle and 
environmental factors on increased oxidative stress, 
overactive immune system, and inactivation of 
anti-aging genes [14] has increased interest in the 
treatment, care, and diagnosis of neuropsychiatric 
disorders-early diagnosis with relevance to anti-aging 
genesis critical to prevent autoimmune reactions 
[3,7,14] associated withmajor subcellular alterations 
such as mitochondrial apoptosis and endoplasmic 
reticulum (ER) stress in neurons [15-21] that may lead to 
accelerated programmed cell death in neuropsychiatric 
conditions and global chronic disease. 
a) Sirtuin 1 and Global chronic disease with relevance 
to ER stress and mitophagy in neuropsychiatric 
disorders
Specific genes and novel mutations were
identified in neuropsychiatric conditions with gene 
variants involved in cognitive disorders in these patients
[22-24].  These genes may not allow early diagnosis and 
N
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reversal of the complications of these neuropsychiatric 
disorders. In recent years the discovery of anti-aging 
genes and their inactivation [25, 26] may now be 
relevant to the epigenetics of neuropsychiatric disorders 
[27, 28]. The anti-aging gene Sirtuin 1 (Sirt 1) has 
become important to neuropsychiatric conditions with its 
connections to schizophrenia, depression, bipolar 
disease and autism [29-36]. Sirt 1 dysregulation is 
critical to the development of global chronic disease 
with Sirt 1 effects on chromatin alterations (modeling) 
that influence the DNA sequence, DNA repair, DNA 
methylation and histone modifications [25, 26].  Sirt 1 is 
a nicotinamide adenine dinucleotide dependent-class III 
histone deacetylase that targets transcription factors 
such as peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC 1-<alpha>), 
mitochondrial biogenesis, p53, pregnane X receptor 
(PXR) to adapt gene expression to metabolic activity, 
insulin resistance and inflammation [25, 26]. Sirt 1 
mediated deacetylation of the transcriptional factor 
FoxO3a represses Rho-associated protein kinase-1 
gene expression was associated with the reduction of 
amyloid beta generation [14]. In mammalian cells, Sirt 1 
is linked to autoimmune disease [3, 7] and the 
regulation of telomere maintenance and length [26].   
Sirt 1 and its association with neuron senescence [37]
was connected to Alzheimer’s disease and other 
neurodegenerative diseases.
Inactivation of anti-aging genes such as Sirt 1 
may supersede the genetic findings in neuropsychiatric 
disorders and the Sirt 1 gene now associated with cell 
Mitochondrial alterations and ER stress in global chronic 
disease have become of principal concern to 
neuroinflammation in neuropsychiatric conditions and 
neurodegenerative diseases. The repression of Sirt 1 in 
global illness [2, 3] and ER stress-induced mitophagy 
(Figure 2) [38-42] may be relevant to the diagnosis and 
treatment of neuropsychiatric patients in various global 
communities. Sirt 1 in neurons is critical for the 
prevention of cholesterol dyshomeostasis with toxic 
amyloid beta formation (Figure 2) involved in ER stress-
induced mitophagy and neuron survival [43]. 
The connections between Sirt 1 and neuropsychiatric 
conditions are relevant to Sirt 1’s role in autoimmune 
disease and amyloid beta aggregation [3, 7, 43]. In the 
developing with increased plasma bacterial 
lipopolysaccharides (LPS), Sirt 1 may be repressed [44] 
with relevance to LPS in cell membranes that bind to 
cholesterol/sphingomyelin domain with an acceleration 
of toxic amyloid beta oligomerization in neuropsychiatric 
disorders [45-47].
In neuropsychiatric disorders [12, 13, 48, 49] 
alterations in neuron membranes have become of prime
concern with relevance to defective phospholipid 
metabolism in these patients. Lipid membrane 
abnormalities may affect dopamine signaling in 
schizophrenia and phospholipase A2 abnormalities 
responsible for altered brain membranes. The defective 
neuron amyloid beta pathway (Figure 2) is now relevant 
to neuropsychiatric disorders such as schizophrenia, 
depression and bipolar disease and applicable to 
disturbed membrane cholesterol homeostasis and toxic 
amyloid beta oligomer formation in neurons (Figure 2). 
In chronic diseases such as NAFLD, obesity, and 
diabetes alterations in membrane phospholipids are 
connected to the defective amyloid beta clearance 
pathway [43, 47] with effects on neuron membranes 
with toxic amyloid beta oligomerization associated with 
neuron cell apoptosis (Figure 2). Phospholipid 
composition such as phosphatidylinositol lower 
membrane cholesterol (Figure 2) and amyloid beta with 
prevention of toxic amyloid beta aggregation [50].
Figure 2: Inactivation of genes such as Sirtuin 1 (Sirt 1) is associated with ER stress and the induction of mitophagy 
in neuropsychiatric disorders. Cholesterol dysregulation and toxic amyloid beta formation are associated with Sirt 1 
inactivation by LPS with relevance to neuropsychiatric diseases in the developing world. Phosphatidylinositol (PI) 
may reduce membrane cholesterol levels and amyloid beta oligomers to treat mitophagy and ER stress in liver and
brain diseases (2). N- Nucleus.
Early Diagnosis and Nutritional Treatment Stabilizes Neuropsychiatric Disorders
abnormalities (Figure 2) in neuropsychiatric conditions. 
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Nitric oxide (NO) is now a crucial player in 
neuropsychiatric disease and associated with
schizophrenia, bipolar disorder and major depression 
[51, 52]. NO as a lipophile acts as an intracellular and
intercellular messenger that is critically regulated by 
cellular Sirt 1 [53, 54] with NO involved in cell 
communication between neuron cells in the brain.       
The connections between the immune system and 
neuropsychiatric diseases involve NO and implicate Sirt 
1 regulation of NO in autoimmune disease [51].         
The importance of Sirt 1 in neuropsychiatric disorders is 
relevant to NO homeostasis as the primary defect 
(Figure 2) with connections to secondary subcellular 
and membrane alterations in neuropsychiatric 
disturbances [51, 52]. 
b) Diagnosis of mitophagy in neuropsychiatric patients 
with global chronic disease
The criteria are allowing reliable diagnostic 
identification of schizophrenia, bipolar disease and 
depression are defined by subjective experiences 
(symptoms), loss of function (behavioral impairments) 
and variable patterns of the disease. Some biological 
markers (genomics, proteomics, metabolomics) were
associated with the disorder, but to date, these markers 
do not have the sensitivity/specificity of a diagnostic test 
[55-60]. The early diagnosis of neuropsychiatric 
disorders now involves measurements of nuclear, 
cellular and plasma Sirt 1 levels (Figure 3) [43, 61]. 
Measurements of magnesium [62, 63] and zinc may be 
vital to prevent inactivation of brain Sirt 1 activity. Sirt 1 
nuclear receptor control of ER-mitochondria interaction 
may need to assess plasma LPS levels to avoid 
complete repression of Sirt 1 and induction of 
mitophagy induced ER stress in neuropsychiatry 
diseases.
Figure 3: Biomarker tests for mitophagy and ER stress in neuropsychiatric disorders were required for reversal and
stabilization of the disease. Genomic, proteomic and lipidomic experiments are critical to assess the induction of 
mitophagy with relevance Sirt 1 and lipid binding protein analysis in plasma and tissues. Plasma lipid measurements 
of cholesterol, ceramide, sphingolipids, and phospholipids (phosphatidylinositol) are essential to determine early 
mitophagy-ER stress disorders in neuropsychiatric disorders.
Lipidomic analysis [64] of plasma lipids 
(sphingolipids/ceramides) may reflect changes in the 
periphery and central nervous system and correlation 
with plasma Sirt 1, ceramide binding proteins and 
sphingolipid transfer proteins may be important in 
neuropsychiatric diseases. Measurements of micro RNA 
(mir-34a, mir-122, mir-132) may indicate repression of 
Sirt 1 [3] and relevant to the lipidomic analysis. The 
levels of plasma heat shock protein (Figure 3) may 
reflect inhibition of Sirt 1 activity and pertinent to 
activation of autoimmune disease [43]. These biomarker 
tests (Figure 3) that are relevant to global chronic illness
[65,66] are now appropriate to the early diagnosis and 
treatment of neuropsychiatric disturbances.
c) Nutritional Biotherapy and Management of 
neuropsychiatric114 patients
In neuropsychiatric disorders such as 
schizophrenia, a healthy and low carbohydrate diet with 
careful nutritional assessment [67, 68] is required to 
prevent obesity, diabetes, and NAFLD and stabilize 
complications of the disease. A systematic review of the 
literature indicates that metabolic abnormalities were
linked to schizophrenia [69]. In depression and mental 
illness a complete nutritional diet [70] is required to 
improve behavior, emotion, and cognition with 
consumption of low carbohydrates, proteins (amino 
acids/brain function, essential fatty acids (omega-3), 
vitamins (B, B12, folate) and minerals (calcium, 
chromium, iodine, iron, lithium, selenium, zinc). Diets 
that contain functional foods such as biologically active 
Sirt 1 activator are now essential to maintain patients 
with neuropsychiatric disorders [64].
Nutritional biotherapy is now critical to the 
maintenance of the calorie sensitive gene Sirt 1 with 
excessive glucose and fatty acid that is involved in Sirt 1 
repression. Early interventions with the use of genomic 
Early Diagnosis and Nutritional Treatment Stabilizes Neuropsychiatric Disorders
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medicine [71, 72] and Sirt 1 activatorsare essential to the 
treatment of autoimmune disease and 
neurodegeneration. Appropriate doses of Sirt 1 
activators such as pyruvic acid, resveratrol, leucine, 
rutin, and alpha lipoic acid will prevent mitophagy and 
ER stress by modulation at the cellular level of 
neuropsychiatric disease. Phosphatidylinositol 
(4gm/day) should be consumed [50] to halt neuron 
membrane cholesterol and amyloid beta disturbances. 
Appetite control (Figure 4) with cautious nutrient 
(glucose/fatty acid) intake will maintain the calorie 
sensitive Sirt 1 activity and stabilize schizophrenia, 
depression and bipolar disease. The contents of 
caffeine (Figure 4) in the diet in neuropsychiatric patients 
should be carefully controlled to prevent caffeine 
associated neuron disturbances in the brain [63]. In the 
developing world with elevated LPS levels [44-47] 
nutritional biotherapy is critical to maintaining Sirt 1 
activity and rapid hepatic drug and xenobiotic 
metabolism [14]. The use of anti-depressants, 
antipsychotics and other drug therapy in 
neuropsychiatric patients require intact hepatic and 
brain Sirt 1 activity. Sirt 1 inhibitors [43, 63] may nullify 
drug therapy with drug-drug interactions (Figure 4) as 
complications of neuropsychiatric disorders. Prevention 
of stress and maintenance of core body temperature 
were required for the prevention of autoimmune disease 
[43, 54] in these patients.
Figure 4: Appetite control is essential to maintain Sirt 1 activityand therapeutic drug metabolism with the prevention 
of drug-drug interactions in neuropsychiatric disorders. Nutrigenomic diets that contain Sirt 1 activators are vital for 
the treatment of neuropsychiatric disease and the prevention of mitophagy induced ER stress. Caffeine intake 
should be controlled to maintain therapeutic drug treatment. Excessive anxiety and pressure should be avoided to 
preserve nitric oxide homeostasis and immune reactions with relevance to autoimmune and neurodegenerative 
diseases.
II. Conclusion
Early diagnosis and the measurement of 
plasma/tissue Sirt 1 levels in neuropsychiatric disorders 
will allow treatment of schizophrenia, depression and 
bipolar disease. Plasma analysis of Sirt 1 with extensive 
lipidomic analysis may indicate the risk of mitophagy 
and ER stress with relevance to autoimmune disease in 
neuropsychiatric disorders. Nutritional biotherapy and 
genomic medicine that involves the activation of Sirt 1 at 
the nuclear receptor level may allow modulation/reversal 
of mitophagy and ER stress in psychiatric disorders and 
neurodegenerative diseases such as Alzheimer/s 
disease, Parkinson’s disease, and Huntington’s disease.
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